U.S. Supreme Court Won’t Review Fosamax MDL Ruling On Preemption
WASHINGTON, D.C. — The U.S. Supreme Court on June 16 denied a drug manufacturer’s petition for certiorari in the long-running Fosamax femur fracture multidistrict litigation, letting stand a Third Circuit U.S....To view the full article, register now.
Already a subscriber? Click here to view full article